High-affinity DNA aptamers: a new drug modality

TAGCyx Biotechnologies uses its proprietary Xenoligo technology platform to generate novel DNA aptamers containing an artificial nucleotide that have high affinity and selectivity for target proteins. TAGCyx is building a pipeline of Xenoligo aptamers and aptamer–drug conjugates, and is looking for global pharmaceutical partners.

1
0
Page of
Go to the profile of TAGCyx Biotechnologies Inc.

TAGCyx Biotechnologies Inc.

TagCyx is a research based company based in Tokyo (Japan), founded in March 2007 as a spin out company of RIKEN. TagCyx’s scientific team has established its proprietary Xenoligo® technology platform, allowing high functional oligonucletide drug discovery. The Xenoligo® platform utilizes genetic alphabet expansion by unnatural base-pairs to generate customized nucleic acid suited for therapeutic applications.

No comments yet.